Crown Bioscience

AUGUST 2, 2021

Interest in IMIDs has grown rapidly in recent years, largely fueled by the view that IMIDs share common inflammatory pathways, and therefore, there is the possibility that novel therapies that work in one IMID may work in other IMIDs.

Disease 52

Disease Drug Development Immune Response Drugs 52

DrugBank

AUGUST 20, 2024

The world of drug discovery is in a state of transformation, with advancements in biotechnology opening doors to new possibilities for targeting previously "undruggable" disease mechanisms. You’ll discover real-world examples, such as the transformation of KRAS from an undruggable target to a success story in targeted therapy.

Therapies 71

Therapies Pharmaceuticals Disease Research 71

DrugBank

MAY 15, 2024

Its structure makes it incredibly difficult for drugs to bind effectively, which has stymied drug development for decades. The binding pockets on KRAS are shallow and polar , not ideal for the kinds of interactions needed for strong, effective drug binding.

Small Molecule 81

Small Molecule Molecular Biology Drugs Disease 81

Vial

MAY 20, 2024

Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline. The two broadest categories of drug development can be separated into the preclinical and clinical research stages.

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

Advarra

AUGUST 16, 2022

The law established the Office of Orphan Products Development , providing financial incentives for pharmaceutical companies to develop orphan drugs and making it more viable to invest in orphan drug research and development. The impact was clear: Between 1983 and 2020, FDA approved 599 orphan drugs.

Disease 52

Disease Clinical Trials FDA Approval FDA 52

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

This improvement stems from several factors, including the FDA’s emergency use authorization (EUA) of a number of therapies found to be safe and effective for COVID-19. ACTIV was founded last April to accelerate drug research that typically requires more than a decade of clinical ups and downs to develop a safe, effective therapy.

Clinical Trials 52

Clinical Trials Trials Hospitals Vaccine 52

Agency IQ

JUNE 9, 2023

The problems: Although the current regulation stimulated orphan drug research, it didn’t do enough The regulation fostered development of medicines for rare diseases since implementation, but not enough. High-priced cell and gene therapies are being increasingly developed for rare diseases.

Marketing 40

Marketing Regulations Biosimilars Drugs 40